In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication

Antimicrobial Agents and Chemotherapy
Steffen WildumPeter Lischka

Abstract

Despite modern prevention and treatment strategies, human cytomegalovirus (HCMV) remains a common opportunistic pathogen associated with serious morbidity and mortality in immunocompromised individuals, such as transplant recipients and AIDS patients. All drugs currently licensed for the treatment of HCMV infection target the viral DNA polymerase and are associated with severe toxicity issues and the emergence of drug resistance. Letermovir (AIC246, MK-8228) is a new anti-HCMV agent in clinical development that acts via a novel mode of action and has demonstrated anti-HCMV activity in vitro and in vivo. For the future, drug combination therapies, including letermovir, might be indicated under special medical conditions, such as the emergence of multidrug-resistant virus strains in transplant recipients or in HCMV-HIV-coinfected patients. Accordingly, knowledge of the compatibility of letermovir with other HCMV or HIV antivirals is of medical importance. Here, we evaluated the inhibition of HCMV replication by letermovir in combination with all currently approved HCMV antivirals using cell culture checkerboard assays. In addition, the effects of letermovir on the antiviral activities of selected HIV drugs, and vice versa, were a...Continue Reading

References

Oct 1, 1990·Antiviral Research·M N Prichard, C Shipman
May 8, 2002·CNS Drugs·Matthias MaschkeHans-Christoph Diener
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·William E DelaneyShelly Xiong
Feb 26, 2005·Journal of Virology·Eva-Maria Borst, Martin Messerle
May 6, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Christoph SteiningerTheresia Popow-Kraupp
Jun 13, 2006·Antiviral Research·Karen K Biron
Dec 12, 2007·The British Journal of Dermatology·W L Ho, G M Murphy
Jan 26, 2008·Archivum Immunologiae Et Therapiae Experimentalis·Naeem Khan
Jul 30, 2008·Current Opinion in Pharmacology·Peter Lischka, Holger Zimmermann
Mar 18, 2009·Antimicrobial Agents and Chemotherapy·Ming-Tain LaiMichael D Miller
Oct 23, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elena LosinaKenneth A Freedberg
Jan 6, 2010·Antimicrobial Agents and Chemotherapy·Peter LischkaHolger Zimmermann
Jul 9, 2010·Lancet·Paul A Volberding, Steven G Deeks
Oct 12, 2010·Clinical Microbiology Reviews·Nell S Lurain, Sunwen Chou
Jan 18, 2011·Hematology/oncology Clinics of North America·Per LjungmanMichael Boeckh
Apr 28, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D R KaulH Rubsamen-Schaeff
Feb 4, 2012·Expert Opinion on Pharmacotherapy·Georg Härter, Detlef Michel
Sep 21, 2012·Current Infectious Disease Reports·Elena Beam, Raymund R Razonable
Oct 11, 2012·Current Opinion in Ophthalmology·Nicholas J Butler, Jennifer E Thorne
Dec 18, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A K Le PageW D Rawlinson
Feb 1, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·C N Kotton
Jul 31, 2013·Transplantation·Camille N KottonUNKNOWN Transplantation Society International CMV Consensus Group
Aug 21, 2013·Antimicrobial Agents and Chemotherapy·Steffen WildumHolger Zimmermann
Oct 30, 2013·Transplant International : Official Journal of the European Society for Organ Transplantation·Susanne StoelbenKlemens Budde
Nov 26, 2013·The Medical Clinics of North America·Jawad A Ilyas, John M Vierling
May 9, 2014·The New England Journal of Medicine·Roy F ChemalyUNKNOWN AIC246 Study Team
May 9, 2014·The New England Journal of Medicine·Paul D Griffiths, Vincent C Emery

❮ Previous
Next ❯

Citations

Aug 18, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Marisa C GasparWilliam Couet
Dec 22, 2016·Expert Opinion on Investigational Drugs·Lyndsey J BowmanDaniel C Brennan
Feb 28, 2017·PLoS Pathogens·Ekaterina MaidjiCheryl A Stoddart
Dec 7, 2017·The New England Journal of Medicine·Francisco M MartyCyrus Badshah
Dec 27, 2018·Journal of Clinical Pharmacology·Aimee C HodowanecMary E Singer
Jan 26, 2020·Current Hematologic Malignancy Reports·Morgan Hakki
Dec 31, 2017·Drugs·Esther S Kim
Feb 18, 2021·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Margaret R JorgensonChristopher M Saddler
May 6, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yuzhen GaoYouming Zhang
Jun 10, 2016·Clinical Microbiology Reviews·Erik De Clercq, Guangdi Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.